RT Journal Article
SR Electronic
T1 Transition Between Treatments: What We Need to Know
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.201331
DO 10.3899/jrheum.201331
A1 Kirsten Minden
A1 Jens Klotsche
YR 2021
UL http://www.jrheum.org/content/early/2021/04/10/jrheum.201331.abstract
AB Recent decades have seen the introduction of many new therapeutics into pediatric rheumatology practice, particularly biologic disease-modifying antirheumatic drugs (bDMARD). These advances are a result of the biotechnological revolution in the pharmaceutical industry, specific legislation for the development of pediatric medicines, and large international collaborative networks.